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Introduction
Antibiotic1 use in animal production has led to 
improved feed use efficiency and increased growth rates. 
In turn, these resulted in reduced food production costs 
and reduced excrement of manure nutrients which may 
cause pollution problems.
On the other hand, antibiotic use leads to antibiotic 
resistance and a possible reduction in effectiveness of 
treatment options for both animals and humans. This 
publication addresses these issues. 
Disease-causing microorganisms2, including 
bacteria­, are the most diverse and numerous organ-
isms on earth. Diverse in their habitat, environmental 
adaptation, and mechanisms of reproduction, they 
have short generations with high multiplication rates. 
Such characteristics help develop antibiotic resistance. 
Resistance has developed to antibiotics used for human 
treatment but very limited evidence is shown for 
development of antibiotic resistance because of its use 
in animal production.
 
Antibiotics Mode of Action 
Antibiotics inhibit or kill susceptible bacteria in four 
broad ways:
• disruption of microbial cell wall synthesis;
• inhibition of DNA replication;
• inhibition of protein synthesis; and
• inhibition of cell division, development, and 
differentiation .
Resistance develops when a susceptible bacterium 
develops an alternative path for its cell functions and 
processes that are no longer inhibited by the antibiotic. 
The most common source of antibiotic resistance 
for microorganisms is genetic modification. The vast 
majority of drug-resistant organisms emerge as a result 
of single- or multiple-gene mutations. Resistance to an 
antibiotic can develop when an organism acquires a for-
eign gene from another microorganism or picks a free or 
“naked” gene source from the environment by a process 
called transformation. 
Resistance mechanisms are often specific to a par-
ticular antibiotic and bacterial species, and a specific 
resistance mechanism may be limited to a specific 
environment . However, the discovery of similar genes 
and mechanisms across unrelated bacteria in some cases 
suggests that such resistance genes have been transferred 
between bacteria.
1Definitions for these terms in bold are given in the Definition of 
Terms section at the end of the publication. 
2The term "microorganism" is used loosely in this publication to 
refer to microscopic, often single-celled organisms causing major 
animal and human diseases. 
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Antibiotic Use in Livestock Production
Antibiotics are used for therapeutic purposes 
to prevent or control the development of disease in 
humans and animals alike. Therapeutic antibiotic 
use is often at a higher dose than “subtherapeutic” 
purpose and is generally administered in water or by 
injection. In livestock production, antibiotics are also 
used at subtherapeutic level to promote growth and 
increase feed efficiency. Subtherapeutic antibiotic use 
in animals is administered as an additive to the feed or 
through an implant . The use of antibiotics in feed is 
a regulated activity under the Code of Federal Regula-
tions, Title 21, Part 558.
For use in the U.S., antibiotics for animal production 
must be approved by the Food and Drug Administration 
after rigorous evaluation for safety against major risk 
factors with respect to the animal, the consumer, and the 
environment. Antibiotics are assessed for:
• efficacy (the ability to achieve the claimed outcomes 
by the manufacturer),
• target animal safety, 
• environmental safety,
• human occupational safety, and
• human food safety.
The use of approved antibiotics is regulated and 
instructions must be followed to avoid unintended con-
sequences. The drug manufacturer, the regulatory agency, 
the veterinarian, the producer, and the producer’s employ-
ees involved in administering the feed additive have collec-
tive responsibility for controlling unintended public health 
impacts of antibiotic use in food-producing animals.
Antibiotics Approved for Animal Production, 
Mode of Action and Quantity Used
Antibiotics for Therapeutic Purpose
Antibiotics are used therapeutically to control an 
infectious disease or treat a sick animal, preferably as 
part of an integrated disease management approach 
that incorporates other management components such 
as minimizing external sources of infection on to the 
farm and other biosecurity measures. Therapeutic anti-
biotic use is restrictively specific as to the type, quantity, 
strength, frequency, length of use, route of administra-
tion, and withdrawal­times (therapeutic regimen) as 
dictated by the manufacturer’s label or by additional 
label instructions from a veterinarian.
Antibiotics for Subtherapeutic Purpose
The use of subtherapeutic antibiotics is an impor-
tant component of modern livestock production. Anti-
biotics are added to feed in regulated small amounts for 
maintaining health, promoting growth, and increasing 
feed efficiency. 
Subtherapeutic use must adhere to manufacturer’s 
label instructions. These instructions help prevent 
adverse effect s on the animals, avoid illegal levels of tis-
sue residue, and allow appropriate withdrawal of the 
antibiotic for the recommended time before the animal 
product enters the food chain. The presence of an anti-
biotic residue in animal products above the regulatory 
standard violates the Code of Federal Regulations, Title 
21, and the animal product can be condemned in accor-
dance with the federal Food, Drug & Cosmetic Act. 
Regular intake of antibiotics as feed additives can 
reduce disease risk and increase nutrient use efficiency 
by reducing production of urea, methane, and ammonia 
in the intestine. The improved efficiency gained through 
antibiotic use decreases the amount of feed and land 
necessary to raise the animals and decreases manure 
production per animal (Table 1).
Commonly Used Antibiotics 
in the Production of Food Animals
A partial list of antibiotics used in the production of 
swine, beef and cow-calf, and poultry is shown in Tables 
2, 3, and 4. The list shows the name of the antibiotic, use 
level, treatment objectives, and the required withdrawal 
time. A complete list of FDA-approved animal drug 
products can also be found in the FDA Green Book avail-
able at http://www.fda.gov/cvm/Green_Book/elecgbook.
html.
Antibiotic feed additive use is not common in milk-
ing dairies. The FDA will not accept drug residue in milk 
or sale of milk from sick animals. Milk is checked by the 
milk plant and by offices such as the office of dairy ser-
vices at the state's department of agriculture. Tests can 
detect a drug in milk from treated animals even when 
this milk has been diluted in the tank by milk from many 
cows.
Milk for human consumption must meet minimum 
safety standards for somatic cell count (about 100,000), 
bacteria counts, and have no antibiotic or chemical 
residues. The FDA’s Pasteurized Milk Ordinance requires 
Grade “A” milk delivered to dairy plants to be screened 
for antibiotic residues prior to processing.
Screening is performed on milk samples obtained 
from milk tank trucks arriving from farms at milk 
assem bly points. At the same time, producer samples 
from individual farms on the load are tested, using the 
same protocol when necessary. 
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Table 1. Physiological, nutritional, and metabolic effects ascribed to antibiotic feed additives in livestock  
(+ shows an increase in response, - shows a decrease in response).
Physiological Effects Nutritional Effects Metabolic Effects
Growth and metabolism of 
harmful gut bacteria
- Energy retention + Ammonia production -
Efficiency of nutrient absorption 
by modifying the gut wall
+ Gut energy loss - Toxic amine production -
Gut absorptive capacity + Nitrogen retention + Alpha-toxin production -
Fecal moisture - Limiting amino acid supply + Fatty acid oxidation -
Mucosal cell turnover - Vitamin absorption + Fecal fat excretion -
Stress - Vitamin synthesis - Liver protein synthesis +
Feed intake + Trace element absorption + Gut alkaline phosphatase +
 Fatty acid absorption + Gut urease -
Glucose absorption + Methane -
Calcium absorption + Toxic amine production -
Plasma nutrients +
Table 2. FDA-approved commonly used antibiotics for therapeutic and subtherapeutic purposes in swine 
production .
Drug
Drug Use Level in Feed (g/ton) and  
Treatment Objective Withdrawal Time (days)
Apramycin 150 (Disease control) 28
Arsanilic­acid 45-90 (Feed efficiency and growth)   5
Bacitracin­methylene­disalicyate 10-30 (Feed efficiency and growth) None
250 (Disease control) None
Bacitracin­zinc 10-15 (Feed efficiency and growth) None
20-40 (Feed efficiency) None
Bambermycins 2 (Feed efficiency and growth) None
2-4 (Growth) None
Carbadox 10-25 (Feed efficiency) 42
50 (Disease control) 42
Chlortetracycline 10-50 (Feed efficiency and growth) None
>50 (Disease control) None
Lincomycin 20 (Feed efficiency and growth) None
40-200 (Disease control) None
Oxytetracycline 10-50 (Feed efficiency and growth)   5
22 (Disease control)   5
Penicillin 10-50 (Feed efficiency and growth) None
Roxarsone­ 23-34 (Feed efficiency and growth)   5
182 (Disease control)   5
Tiamulin­hydrogen­fumerate 10-11 (Feed efficiency and growth) None
35-200 (Disease control) 2-7
Tilmicosin 181-363 (Disease control)    7
Tylosin­ 10-20 Finisher (Feed efficiency and growth) None
20-40 Grower (Feed efficiency and growth) None
20-110 Starter (Feed efficiency and growth) None
10-100 (Disease control) None
Virginiamycin 6-10 (Feed efficiency and growth) None
>25 (Disease control)
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Table 3. FDA-approved commonly used antibiotics for therapeutic and subtherapeutic purpose in beef 
and cow-calf1 production.
Drug Drug Use Level in Feed (mg per head per day) and 
Treatment Objective
Withdrawal Time (days)
Bacitracin­zinc 35-70 (Feed efficiency and growth) None
Bambermycins 1-5 (Feed efficiency and growth)
2-45 (Pasture, slaughter, feeder cattle growth)
None
None
Chlortetracycline 350 (Disease control) 2
Laidlomycin 5-10 (Feed efficiency and growth) None
Lasalocid 10-30 (Feed efficiency and growth) None
Monensin 5-30 (Feed efficiency, growth, and disease control)
25-400 (Intensive feeding and weight gain)
None
None
Oxytetracycline 75 (Feed efficiency and growth)
75 (Disease control) 




Tylosin 8-10 (Disease control) None
Virginiamycin 10-25 (Feed efficiency, growth, and disease control) None
1Foraging pasture constitutes the major proportion of a cow-calf ration as compared to purchased feeds. Hence antibiotics are formulated on a 
per-head basis.
Table 4. FDA-approved commonly used antibiotics for therapeutic and subtherapeutic use in poultry 
production 
Drug Drug Use Level in Feed (g/ton) and Treatment Objectives Withdrawal Time (days)
Arsanilic­acid­ 75-120 (Feed efficiency, growth, and pigmentation) 5
Avilamycin 5-10 None
Bacitracin 4-50 (Feed efficiency and growth) None
Bambermycins 1-20 (Feed efficiency and growth) None
Chlortetracycline 10-100 (Feed efficiency, growth, and disease control) None
Lincomycin 2-4 (Feed efficiency and growth) None
Oxytetracycline 5-50 (Feed efficiency, growth, and disease control) 0-3 
Penicillin 2-50 (Feed efficiency and growth) None
Roxarsone 23-46 (Feed efficiency, growth, and pigmentation) None
Spiramycin­(Banned­in­EU1) 5-20 None
Avoparcin­(Banned­in­EU) 7.5-15 None
Tylosin­(Banned­in­EU) 4-50 (Feed efficiency and growth) None
Virginiamycin­(Banned­in­EU) 5-20 (Feed efficiency and growth) None
1EU = European Union.
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A tank truck sample that tests positive will not be used 
for human consumption. Moreover, the presence of anti-
biotics in milk interferes with the manufacture of several 
dairy products such as delaying starter activity for cheese, 
butter, and yogurt . Antibiotics also decrease the acid and 
flavor production associated with butter manufacturing, 
in addition to reduced curdling of milk.
Human and Environmental Health Concern
Antibiotic Toxicity
To ensure consumer safety from antibiotic residues 
in food animals, the drug sponsor conducts a number 
of studies assessing the effect of the product on sys-
temic toxicity, repeat dose toxicity, reproductive toxicity, 
developmental toxicity, genotoxicity, carcinogenicity, and 
human intestinal flora. The FDA reviews the methodol-
ogy and results to set acceptable daily intake (ADI) and 
maximum residue limits (MRL) and associated with-
drawal time to allow the drug residue to deplete below 
calculated MRL and ADI levels. Withdrawal time is 
product-specific. A similar product could have different 
withdrawal times depending on the difference in formu-
lation of the product for a specific purpose.
Toxicology studies determine the dose at which no 
adverse effect is observed. This dose is used to calculate: 
1) the amount of drug residue that can be consumed by 
an adult daily for a lifetime, without appreciable risk to 
human health; and 2) the maximum residue limits of a 
drug in a treated animal. Producers are required to fol-
low label instructions and withdrawal times (Tables 2, 
3, and 4) to keep drug residue in animal products from 
reaching consumers.
According to a recent review by Lee and group, 
the measured level of antibiotic concentrations in the 
environment , including concentrations found in animal 
manure and lagoon effluent, are lower than the level 
believed to cause observable adverse effect on routinely 
tested organisms. However, this general observation 
should be understood in line with the limited research 
information and limited field sample analysis poten-
tial.  There are also some reported effects on non-
target organisms under extreme conditions, which 
include an observed negative effect of antibiotics on 
microorganisms involved in normal soil processes such 
as nitrification and organic matter decomposition. 
Plant uptake of antibiotics from manure-applied 
plots has been reported, although observed levels are 
extremely low and not of concern to humans and ani-
mals feeding on these plants and plant products. Uptake 
of sulfamethazine (an antibiotic) by corn, lettuce, and 
potatoes has been documented with concentrations in 
plant tissue ranging from 0.1 to 1.2 ppm dry weight. Sul-
famethazine concentration in plant tissue increased, with 
concentration in the applied manure. However, the total 
accumulation of sulfamethazine in the plant tissue after 
45 days of active growth was less than 0.1 percent of the 
total applied to soil in manure.
Antibiotic toxicity to humans is unlikely to be a 
concern from antibiotics that may appear in animal 
products or food crops receiving manure. Current FDA 
approval processes have a proven history of protecting 
human health from antibiotic residue in animal prod-
ucts. Currently, toxicity to humans via soil or water path-
ways appears very unlikely. However, additional research 
may be needed to determine toxicity of antibiotics to 
helpful microorganisms in manure and the soil.
Microbial Resistance to Antibiotics
The use of antibiotics may eliminate susceptible 
microorganisms, leaving resistant ones behind. Such 
resistant bacteria can cause an infection both in humans 
and animals and may not respond to regular antibiotic 
treatments. The emergence of such antibiotic-resistant 
bacteria is a serious concern. People or animals infected 
with resistant bacteria may be sick for a longer time than 
with an infection caused by bacteria that is easily treat-
able with common antibiotics.
The FDA has published guidelines for an evidence-
based approach to prevent antimicrobial resistance in 
humans that may result from the use of antibiotics in 
animals. This regulatory tool, known as Guidance #152, 
is a checklist of points to consider when weighing the 
potential human impact of a new animal drug. An elec-
tronic copy of Guidance #152 is available at http://www.
fda.gov/cdrh/oivd/guidance/152.pdf.
The National Antibiotics Resistance Monitoring 
System (NARMS) monitors resistance to antimicrobial 
drugs used in humans and food animals. Established in 
1996, NARMS is a collaborative effort of the FDA, the 
Centers for Disease Control and Prevention (CDC), and 
the U.S. Department of Agriculture (USDA) facilitating a 
nationwide system to track the change in susceptibility of 
microorganisms to a wide range of antibiotics important 
in human and animal medicine. Each year, samples are 
taken and tested to determine changes over time in the 
resistance of certain gut bacteria to selected antimicro-
bial drugs.
For example, approximately 30,000 samples of Sal-
monella isolates were tested from 1997 to 2003 and about 
1 percent were found to be resistant. See the following 
link for details: http://www.fda.gov/cvm/NARMSSB-
07White.htm. There is an increasing trend in resistance 
for the isolates from human sources, but no clear trend 
for isolates taken from food animals except for a slight 
increase of Ceftiofur resistance in Salmonella among 
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cattle. The antibiotic drugs tested are selected based on 
their importance in human and animal medicine (Table 
5). Anti biotics of significant importance in human medi-
cine may be banned for use in animal production or 
restricted to the therapeutic use under the prescription 
or super vision of a veterinarian. For example, in July 
2008, the FDA issued a prohibitive order limiting extra-
label­use of Cephalosporins in food-producing animals, 
to limit the development of microbial resistance to this 
class of drugs based on evidence gathered by NARMS. 
There is genuine concern that using antibiotics in 
large-scale animal production may contribute to more 
instances of antibiotic resistance. However, the consensus 
of reports from the FDA and other sources that looked 
objectively into this issue found no conclusive evidence 
of food-animal antibiotic use leading to resistance devel-
opment in humans.
The FDA has acted and initiated the necessary 
measures when there was a confirmed link in resistant 
development to the use of a certain antibiotic in food 
animal production and will likely continue to do so in 
the future. However, constant assessment of this poten-
tial risk will need to continue in the future.
Economic Impact of Antibiotics 
in Animal Production 
Using antibiotics increases an animal’s daily weight 
gain and reduces costs and feed inputs per unit of animal 
product. Antibiotic use also improves feed efficiency by 
reducing maintenance costs of the animal and provid-
ing protection at critical growth stages. Antibiotics also 
reduce mortality. The increased production efficiency 
from using antibiotics is expected to:
• reduce the number of animals needed to produce a 
given amount of animal product such as beef;
• reduce the level of inputs such as gasoline, fertilizer, 
and insecticide used to produce feed; and 
• reduce the amount of manure produced per unit of 
animal production. 
Therefore, gained efficiency in animal production 
from using antibiotics should benefit the environment 
and food supply. However, economic and environmental 
benefits from antibiotic use in animal production must 
be weighed against the risk for the development of resis-
tance.
Management Options to Mitigate 
Antibiotic Resistance
Minimizing antibiotic resistance risk, means using 
antibiotics appropriately and judiciously. The American 
Veterinary Medical Associations (AVMA) and the 
FDA Center for Veterinary Medicine have developed 
guidelines on the judicious use of anti biotics in order 
to optimize resource use efficiency and to minimize 
the development of antibiotic resistance. See this 
link for details: http://www.avma.org/issues/default.
asp#antimicrobials.
1. Prevent disease by providing integrated and sound 
management systems:
• providing best-practice sanitation and hygiene;
• providing high-quality feed and protection from 
the elements to reduce stress;
• implementing biosecurity measures;
• performing regular health exams;
• using vaccines; and
• controlling parasites.
2. Accurate and timely diagnosis of sick animals 
ensures proper and timely treatment methods. 
3. If you must use antibiotics, work with a veterinar-
ian to select the treatment option and to prepare a 
written treatment protocol. Use proper dose, route, 
treatment, and withdrawal time.
4. Treat the appropriate animals and the fewest number 
of animals possible.
Table 5. Ranking of antibiotics for monitoring the emergence of resistance in the U.S. 
Critically Important or High Concern Highly Important or Medium Concern Important or Low Concern
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lincosamides, all of which are of direct importance in 
human medicine. In Sweden, the ban of subtherapeu-
tic antibiotics caused the age-to-30 kg body weight to 
increase by two days in pigs and increased the problems 
of necrotic enteritis in broilers. The ban did not affect 
egg production in layers , growth rate in turkeys, or pro-
ductivity in specialized beef production. The Swedish 
Animal Health Service concluded poultry, calves, and 
pigs can be reared without continuous use of growth 
promoters, if the bene fits of other production practices 
such as hygiene are maximized.
The ban on antibiotic feed additives in Europe 
reduced the incidence of resistance in indicator bacteria 
in raw food products of animal origin. While the carriage 
of certain resistant pathogens among healthy individu-
als has diminished, there has been no apparent positive 
impact on the level of antibiotic resistance in human 
patients or in hospitals. Moreover, the incidence of 
food-borne disease continued to rise in Europe for some 
bacteria such as Salmonella, highlighting the complexity 
of any potential relationship between antibiotic use in 
livestock and antibiotic-resistant disease in humans.
Conclusions
Using antibiotics to increase feed efficiency or for 
therapeutic purposes will contribute to the emergence 
of resistant microorganisms. At this time, there’s limited 
evidence that this resistance impacts human health. 
However, this risk cannot be ignored. Current regulation 
of antibiotic use for animal health, field monitoring of 
resistance, and research will be essential to understand 
and minimize these risks. 
Important points to take away from this publication 
are the following:
• All antibiotics should be used judiciously.
• Microorganisms are constantly mutating or 
exchanging DNA with each other and with the 
environment, which could result in the develop-
ment of resistance for existing antibiotics. Resis-
tance development is a natural process as much as 
it is induced by the presence of antibiotics in the 
environment.
• Regulations are in place to reserve some broad 
spectrum antibiotics of critical importance for 
human treatment. 
• The use of antibiotics increases selection pres-
sure for microbial resistance. However, the issue 
is complex and a link of increased microbial resis-
tance in human illnesses to a single factor such as 
the use of antibiotics in livestock production has 
not been verified. 
5. Establish written protocols when using antibiotics.
6. Keep records of animal or group identification, drug 
used, date treated, dosage used, route and location 
for administration, who administered the product, 
and any other useful information.
7. Work with a veterinarian to determine the most 
effective therapy, and maintain a working relation-
ship commonly referred to as “valid veterinarian-
 client-patient-relationship.” This means the 
veterinarian knows the operation, the management 
of the operation, the livestock, and is involved in any 
diagnosis, treatment, and follow-up.
8. Use antibiotics and other medications as ordered.  
It is the law.
9. Train people who treat livestock on your farm 
operation .
10. Minimize environmental contamination. 
Manure storage and treatment options may provide 
additional means for reducing antibiotic risk in manure. 
According to a study from Colorado, manure type and 
treatment time determine the level of break-up for three 
antibiotics (Chlortetracyline, Tylosin, and Monensin) 
from manure before field application.
High-intensity management at storage (amending, 
watering, and turning) reduced the half-life of the three 
antibiotics to 4 to 15 days while watering or turning 
alone reduced the half-life to 8 to 30 days. Thus, a 40-
day composting period would reduce concentrations by 
approximately 94 percent for the intensively managed 
compost system (assumes 10-day half-life) and by 75 
percent for the less intensive composting management 
(20-day half-life). Additional reductions will occur dur-
ing stockpiling or storage. More research is needed on 
treatment or management options and their value for 
reducing antibiotic concentration. 
Impact of Eliminating Antibiotics: 
Case Studies 
The recent subtherapeutic antibiotic ban in 
Europe provides the opportunity to observe the con-
sequences of antibiotic withdrawal. In Europe, the ban 
of subtherapeutic use of antibiotics has been reported 
by some to result in deterioration in animal health, 
includ ing increased diarrhea, weight loss, and mortal-
ity due to Escherichia coli and Lawsonia intracellularis 
in early post-weaning pigs, and clostridial necrotic­
enteritis in broilers . Furthermore, as a result of these 
infections, there is an increase in usage of therapeutic 
antibiotics , including that of tetracycline, aminoglyco-
sides, trimethoprim/sulphonamide , macrolides, and 
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• Strict regulations are in place to limit the transfer 
of antibiotic residue to consumers through animal 
products of treated animals, as well as to prevent 
antibiotic toxicity concerns from food products of 
treated animals. 
• Antibiotics are detected in manures, soils, and 
water but at concentrations below levels that cause 
toxic effects on non-target organisms includ-
ing humans. However, these concentrations may 
increase the development of antibiotic resistance.
Definition of Terms
Antimicrobial: a broad class of natural, synthetic, or semi-synthetic products that kill or inhibit the growth 
of bacteria or other microorganisms. Anti microbials include antibiotics and these terms are often used 
synonymously.
Antibiotics: a substance that is naturally produced by a microorganism that can kill or inhibit the growth of other 
microorganisms at a very low concentration.
Bacteria:­single-cell organisms that may cause disease in animals and humans and are treated by antibiotics. Other 
disease-causing organisms, such as viruses, are not treated by antibiotics. 
Extra-label­use­of­antibiotic:­the actual or intended use of a drug in a manner not in accordance with the 
approved labeling. The provision for such use establishes certain conditions under which veteri narians are 
permitted to use approved animal or human drugs in an extra-label manner in animals . (This includes what is 
commonly known as subtherapeutic­use.) 
Microorganisms­(for the purposes of this guide): single-celled organisms causing major animal and human 
diseases .
Necrotic­enteritis­is a disease caused by Clostridium perfringens. Signs include droopiness, lack of appetite, diarrhea, 
ruffled feathers, and mortality in the flock, sometimes occurring quite suddenly. The disease is common at a 
young age and rarely occurs after 30 days of age. 
Subtherapeutic­use: the use of antibiotics below a disease treatment or control threshold for the purpose of 
improved feed efficiency or weight gain. “Subtherapeutic ” is a term mainly adopted by organizations and 
individuals questioning the use of antibiotics for purposes other than the treatment of diseased animals or to 
prevent the development of a disease.
Therapeutic­use: the use of antibiotics for the treatment of infectious diseases. Therapeutic antibiotics are given at 
a higher dose than subtherapeutics and are generally administered in water or by injection. 
Withdrawal­(withholding)­time: The time from when an animal was last given a drug to when it is considered 
safe for human consumption (marketing of the animal product).
• Reduced antibiotic resistance development in ani-
mal agriculture currently focuses on use of best-
management practices in the use of antibiotics as 
developed by the AMVA and FDA.
• Recent efforts to ban subtherapeutic use of anti-
biotics in animal agriculture in Europe have 
not clearly reduced antibiotic-resistant disease 
in humans to date, and may result in decreased 
productivity and other negative environmental 
consequences.
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